Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text

Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.

Valerie A. Fadok, Donna L. Bratton, Anatole Konowal et al. · Journal of Clinical Investigation · 1998 · 3.1K citations · Full text

Immunology, Immune Regulation, Cell Death +20

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al. · Journal of Clinical Oncology · 2000 · 1.4K citations

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

Shumei Kato, Aaron M. Goodman, Vighnesh Walavalkar et al. · Clinical Cancer Research · 2017 · 837 citations · Full text